Oxford BioTherapeutics Ltd has appointed Eugen Leo, previously an executive at Micromet (Amgen Inc), as head of clinical development. Oxford BioTherapeutics is developing antibody-drug conjugates to treat cancer. Dr Leo has more than 15 years of experience in clinically testing candidate antibodies, kinase inhibitors, vaccines and antisense molecules. After working at Micromet, he held senior positions at Johnson & Johnson Inc and Merck Serono. Dr Leo is a board-certified haematologist and medical oncologist.
Oxford BioTherapeutics announced the appointment on 8 July 2014.
Copyright 2014 Evernow Publishing Ltd